Difference between revisions of "Ivosidenib (Tibsovo)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/idh1-inhibitor-ag-120 NCI Drug Dictionary]: An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/idh1-inhibitor-ag-120 NCI Drug Dictionary]: An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Acute_myeloid_leukemia,_IDH-mutated|IDH1-mutated AML]] | |
| − | * | + | |
| + | ==History of changes in FDA indication== | ||
| + | * 7/20/2018: Granted FDA approval "for adult patients with relapsed or refractory [[Acute_myeloid_leukemia,_IDH-mutated|acute myeloid leukemia (AML) with a susceptible IDH1 mutation]] as detected by an FDA-approved test." | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' AG-120 | ||
| + | *'''Brand name:''' Tibsovo | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 11: | Line 17: | ||
[[Category:IDH1 inhibitors]] | [[Category:IDH1 inhibitors]] | ||
| − | [[Category: | + | [[Category:Acute myeloid leukemia medications]] |
| + | |||
| + | [[Category:Drugs FDA approved in 2018]] | ||
Revision as of 22:17, 20 July 2018
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 7/20/2018: Granted FDA approval "for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test."
Also known as
- Code name: AG-120
- Brand name: Tibsovo